Please assess the completion status of the following clinical trial:

Trial Title: 12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to provide written informed consent~* Documentation of non-cirrhotic or cirrhotic status~* HIV-1 infection~* HIV antiretroviral treatment status (ART), CD4+ T-cell (CD4) count and HIV-1 RNA as follows: (1) not on ART with CD4 count \>500 cells/mm\^3 within 42 days of study entry, (2) elite controller not on ART with CD4 \>200 cells/mm\^3 within 42 days of study entry and HIV-1 RNA \<500 copies/mL on all measurements within 48 weeks prior to study entry, (3) on a stable protocol-approved ART with CD4 count \>200 cells/mm\^3 and HIV-1 RNA \<50 copies/mL within 42 days of study entry~* HCV GT-1 within 12 months prior to study entry~* Prior virologic treatment failure with SOF-containing regimen (SOF/RBV, SOF/PEG/RBV, and SOF/SIM)~* Body mass index (BMI) ≥18 kg/m\^2 within 42 days prior to study entry~* Certain laboratory values obtained within 42 days prior to study entry~* Hemoglobin ≥12.0 g/dL for male, ≥11.0 g/dL for female participants~* Aspartate aminotransferase (AST) (SGOT) and Alanine aminotransferase (ALT) (SGOT) \<10 x ULN~* For female participants of reproductive potential, a negative serum pregnancy test with a sensitivity of at least 25 mIU/mL performed at screening and within 48 hours prior to study entry~* Agreement to use at least two reliable forms of contraceptive simultaneously while receiving study treatment and for 6 months afterward~* Intention to comply with the dosing instructions and study schedule of assessments~Exclusion Criteria:~* Receipt of any investigational drug or device within 60 days prior to study entry~* Prior exposure to a DAA other than SOF and SIM~* Chronic liver disease of a non-HCV etiology~* Presence of active or acute AIDS-defining opportunistic infections within 42 days prior to study entry~* Active, serious infection (other than HIV-1 or HCV) requiring parenteral antibiotics, antivirals, or antifungals within 42 days prior to study entry~* Hepatitis B virus (HBV) infection (defined as HBsAg positive) within 42 days prior to study entry~* History of clinically significant hemoglobinopathy~* Chronic current use of systemically administered immunosuppressive agents~* History of solid organ transplantation~* Current or prior history of clinical hepatic decompensation~* History of a gastrointestinal disorder (or postoperative condition) that could interfere with the absorption of the study drug~* History of significant or symptomatic pulmonary disease, cardiac disease, or porphyria that in the opinion of the investigator would interfere with the study~* History of difficulty with blood collection and/or poor venous access for the purposes of phlebotomy~* Active drug or alcohol use or dependence~* Use of any prohibited concomitant medications per the LDV/SOF product labeling, within 42 days prior to study entry~* Known hypersensitivity to RBV, SOF, LDV, their metabolites, or formulation excipients or any other contraindication to the use of RBV, SOF or LDV~* Currently receiving zidovudine (ZDV), didanosine (ddI), stavudine (d4T) or tipranavir~* Acute HIV infection defined as the phase immediately following infection during which anti-HIV antibodies are undetectable~* Known hepatocellular carcinoma~* Breastfeeding or pregnancy~* A male participant with a pregnant female partner~* Receipt of colony stimulating agents, including but not limited to erythropoietin, within 42 days prior to study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: LDV/SOF + RBV (Type: EXPERIMENTAL): Ledipasvir/sofosbuvir + ribavirin for 12 weeks, followed by 24 weeks of post-treatment follow-up.
- Arm B: LDV/SOF (Type: EXPERIMENTAL): Ledipasvir/sofosbuvir for 24 weeks, followed by 24 weeks of post-treatment follow-up.

Based on this trial design, predict the completion outcome and termination type (if applicable).